192 related articles for article (PubMed ID: 26484876)
21. Depressive-like phenotype induced by AAV-mediated overexpression of human α-synuclein in midbrain dopaminergic neurons.
Caudal D; Alvarsson A; Björklund A; Svenningsson P
Exp Neurol; 2015 Nov; 273():243-52. PubMed ID: 26363495
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic effects of repetitive transcranial magnetic stimulation in an animal model of Parkinson's disease.
Lee JY; Kim SH; Ko AR; Lee JS; Yu JH; Seo JH; Cho BP; Cho SR
Brain Res; 2013 Nov; 1537():290-302. PubMed ID: 23998987
[TBL] [Abstract][Full Text] [Related]
23. α-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model.
Sanchez-Guajardo V; Annibali A; Jensen PH; Romero-Ramos M
J Neuropathol Exp Neurol; 2013 Jul; 72(7):624-45. PubMed ID: 23771222
[TBL] [Abstract][Full Text] [Related]
24. Potential role of α-synuclein in neurodegeneration: studies in a rat animal model.
Stoica G; Lungu G; Bjorklund NL; Taglialatela G; Zhang X; Chiu V; Hill HH; Schenk JO; Murray I
J Neurochem; 2012 Aug; 122(4):812-22. PubMed ID: 22639889
[TBL] [Abstract][Full Text] [Related]
25. Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity.
Gaugler MN; Genc O; Bobela W; Mohanna S; Ardah MT; El-Agnaf OM; Cantoni M; Bensadoun JC; Schneggenburger R; Knott GW; Aebischer P; Schneider BL
Acta Neuropathol; 2012 May; 123(5):653-69. PubMed ID: 22361813
[TBL] [Abstract][Full Text] [Related]
26. A comprehensive study on long-term injury to nigral dopaminergic neurons following intracerebroventricular injection of lipopolysaccharide in rats.
Zhou Y; Zhang Y; Li J; Lv F; Zhao Y; Duan D; Xu Q
J Neurochem; 2012 Dec; 123(5):771-80. PubMed ID: 22957701
[TBL] [Abstract][Full Text] [Related]
27. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
[TBL] [Abstract][Full Text] [Related]
28. Cellular models for Parkinson's disease.
Falkenburger BH; Saridaki T; Dinter E
J Neurochem; 2016 Oct; 139 Suppl 1():121-130. PubMed ID: 27091001
[TBL] [Abstract][Full Text] [Related]
29. Longitudinal and parallel monitoring of neuroinflammation and neurodegeneration in a 6-hydroxydopamine rat model of Parkinson's disease.
Maia S; Arlicot N; Vierron E; Bodard S; Vergote J; Guilloteau D; Chalon S
Synapse; 2012 Jul; 66(7):573-83. PubMed ID: 22337286
[TBL] [Abstract][Full Text] [Related]
30. Neuronal vulnerability in Parkinson's disease.
Double KL
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S52-4. PubMed ID: 22166454
[TBL] [Abstract][Full Text] [Related]
31. Tissue engineered nigrostriatal pathway for treatment of Parkinson's disease.
Struzyna LA; Browne KD; Brodnik ZD; Burrell JC; Harris JP; Chen HI; Wolf JA; Panzer KV; Lim J; Duda JE; España RA; Cullen DK
J Tissue Eng Regen Med; 2018 Jul; 12(7):1702-1716. PubMed ID: 29766664
[TBL] [Abstract][Full Text] [Related]
32. α-synuclein promotes neuroprotection through NF-κB-mediated transcriptional regulation of protein kinase Cδ.
Aoki R; Li YR
Sci Signal; 2011 Oct; 4(195):jc6. PubMed ID: 22009151
[TBL] [Abstract][Full Text] [Related]
33. Berberine prevents nigrostriatal dopaminergic neuronal loss and suppresses hippocampal apoptosis in mice with Parkinson's disease.
Kim M; Cho KH; Shin MS; Lee JM; Cho HS; Kim CJ; Shin DH; Yang HJ
Int J Mol Med; 2014 Apr; 33(4):870-8. PubMed ID: 24535622
[TBL] [Abstract][Full Text] [Related]
34. The effect of repetitive transcranial magnetic stimulation on a model rat of Parkinson's disease.
Yang X; Song L; Liu Z
Neuroreport; 2010 Mar; 21(4):268-72. PubMed ID: 20087233
[TBL] [Abstract][Full Text] [Related]
35. Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra.
Klein RL; King MA; Hamby ME; Meyer EM
Hum Gene Ther; 2002 Mar; 13(5):605-12. PubMed ID: 11916484
[TBL] [Abstract][Full Text] [Related]
36. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys.
Recasens A; Dehay B; Bové J; Carballo-Carbajal I; Dovero S; Pérez-Villalba A; Fernagut PO; Blesa J; Parent A; Perier C; Fariñas I; Obeso JA; Bezard E; Vila M
Ann Neurol; 2014 Mar; 75(3):351-62. PubMed ID: 24243558
[TBL] [Abstract][Full Text] [Related]
37. Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease.
Yamada M; Mizuno Y; Mochizuki H
Hum Gene Ther; 2005 Feb; 16(2):262-70. PubMed ID: 15761265
[TBL] [Abstract][Full Text] [Related]
38. Targeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in Mouse.
Song LK; Ma KL; Yuan YH; Mu Z; Song XY; Niu F; Han N; Chen NH
PLoS One; 2015; 10(6):e0131281. PubMed ID: 26114655
[TBL] [Abstract][Full Text] [Related]
39. FOXO3 determines the accumulation of α-synuclein and controls the fate of dopaminergic neurons in the substantia nigra.
Pino E; Amamoto R; Zheng L; Cacquevel M; Sarria JC; Knott GW; Schneider BL
Hum Mol Genet; 2014 Mar; 23(6):1435-52. PubMed ID: 24158851
[TBL] [Abstract][Full Text] [Related]
40. The Parkinson's disease-related protein DJ-1 protects dopaminergic neurons in vivo and cultured cells from alpha-synuclein and 6-hydroxydopamine toxicity.
Batelli S; Invernizzi RW; Negro A; Calcagno E; Rodilossi S; Forloni G; Albani D
Neurodegener Dis; 2015; 15(1):13-23. PubMed ID: 25500798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
